

# *In vitro* manogepix susceptibility testing of South African *Emergomyces africanus*, *Emergomyces pasteurianus*, and *Blastomyces emzantsi* clinical isolates

Silondiwe P. Nzimande,<sup>1</sup> Nelesh P. Govender,<sup>1,2,3</sup> Tsidiso G. Maphanga<sup>1</sup>

**AUTHOR AFFILIATIONS** See affiliation list on p. 3.

**ABSTRACT** We performed *in vitro* antifungal susceptibility testing of manogepix against the yeast phase of 78 *Emergomyces africanus*, 2 *Emergomyces pasteurianus*, and 5 *Blastomyces emzantsi* isolates using a reference broth microdilution method following Clinical and Laboratory Standards Institute recommendations. All three pathogens had low minimum inhibitory concentrations ranging from <0.0005 to 0.008 mg/L. Manogepix should be investigated in animal models and potentially in future human clinical trials for endemic mycoses.

**KEYWORDS** manogepix, APX001A, antifungal susceptibility testing, thermally dimorphic fungi, emergomycosis, blastomycosis

The fungal genera *Emergomyces*, *Blastomyces*, *Histoplasma*, and *Sporothrix* are endemic to the Southern African region. The first three are phylogenetically related thermally dimorphic fungal genera and belong to the family Ajellomycetaceae (1). *Emergomyces africanus* is the main cause of emergomycosis in Southern Africa among people living with HIV (2). Although *E. pasteurianus* is of worldwide distribution, a few cases have been detected in South Africa. Blastomycosis, caused in South Africa by two species namely *Blastomyces emzantsi* and *Blastomyces percursus*, is less frequently diagnosed compared to emergomycosis (2). For both emergomycosis and blastomycosis, there are no comparative treatment trials. Non-randomized studies, case series, and expert opinions have been used to justify antifungal treatment recommendations. The recommended initial treatment for severe forms of emergomycosis and blastomycosis is amphotericin B, either liposomal or deoxycholate formulations, followed by a step-down to itraconazole (3). Manogepix is a first-in-class small-molecule antifungal agent that targets the highly conserved Gwt1 enzyme and blocks glycosylphosphatidylinositol post-translational modification, which facilitates anchoring of surface proteins to the fungal cell membrane (4, 5). While manogepix has been found to be highly active *in vitro* against clinical isolates of *Coccidioides* and *Histoplasma* (6, 7), *in vitro* testing has not been performed for other thermally dimorphic fungi. We performed *in vitro* manogepix susceptibility testing for three thermally dimorphic fungi, two of which are uniquely associated with human disease in Southern Africa.

## Isolates

We included 78 *Emergomyces africanus* and two *Emergomyces pasteurianus* isolates collected through passive laboratory surveillance performed by the National Institute for Communicable Diseases (NICD) from 2008 to 2021 in South Africa. Of the eight *B. emzantsi* isolates in the NICD's culture collection of pathogenic fungi, only five were included; these had been isolated from clinical cases between 1967 and 1999. *Blastomyces percursus* was excluded from the study because the revival of isolates stored at –70°C

**Editor** Andreas H. Groll, University Children's Hospital Münster, Münster, Germany

Address correspondence to Silondiwe P. Nzimande, SilondiweN@nicd.ac.za.

The authors declare no conflict of interest.

See the funding table on p. 3.

**Received** 29 August 2023

**Accepted** 6 October 2023

**Published** 16 November 2023

Copyright © 2023 American Society for Microbiology. All Rights Reserved.

in the culture collection proved to be very time-consuming, and the study period was limited.

### Fungal identification methods

We re-confirmed the identification of all the isolates by conventional PCR and sequencing of the internal transcribed spacer regions of the ribosomal gene before antifungal susceptibility testing. The mycelial phase on Sabouraud agar [Diagnostic Media Products (DMP), Johannesburg, South Africa] was converted to the yeast phase using brain heart infusion agar (DMP) and incubated at 37°C for up to 7 days. All testing was performed in a biosafety level 2 facility with the use of a class II biosafety cabinet and personal protective equipment, including N95 masks. We limited our work to the mold phase as far as possible. We worked primarily with the yeast phase because this is the pathogenic form in human disease and for laboratory safety reasons.

### Antifungal susceptibility testing

Manogepix susceptibility testing was conducted for the yeast phase using a broth microdilution (BMD) method. Manogepix powder was donated by Amplyx/Pfizer (NY, USA). We prepared BMD panels as per Clinical and Laboratory Standards Institute (CLSI) M27 recommendations with some modifications (8). Since there are no standardized methods for susceptibility testing of thermally dimorphic fungi, we followed CLSI methods but used a larger-than-recommended and previously validated inoculum (9) of 1 McFarland and a prolonged incubation time of 7 days to facilitate growth and visual endpoint determination (9). For test isolates, the minimum inhibitory concentration (MIC) was defined as the lowest concentration that inhibited growth by 50% relative to the positive (growth) control. We included the following quality control strains in each testing run: *Candida parapsilosis* American Type Culture Collection (ATCC) 22019 and *Candida albicans* ATCC 90028 as per the antifungal manufacturer's recommendations. For all test runs, MIC ranges for the quality control strains, read at 24 h, were within the recommended ranges.

### Activity of manogepix against *Emergomyces* and *Blastomyces* isolates

*E. africanus* manogepix MICs ranged from 0.0005 to 0.008 mg/L (Table 1). Of the 78 *E. africanus* isolates tested, 14 (18%) had an MIC of  $\leq 0.0005$  mg/L. The remaining isolates had an MIC that ranged from 0.001 to 0.008 mg/L. Only two *E. pasteurianus* isolates were tested and both had an MIC of  $<0.0005$  and 0.004 mg/L, respectively. For the five *B. emzantsi* isolates tested, the MIC range was 0.0005–0.004 mg/L.

We conducted *in vitro* antifungal susceptibility testing in the yeast phase of 78 *E. africanus*, 2 *E. pasteurianus*, and 5 *B. emzantsi* isolates and found exceedingly low manogepix MICs ranging from  $<0.0005$  to 0.008 mg/L for all three pathogens. While there are no established clinical breakpoints for manogepix, the very low MICs provide evidence of potent *in vitro* activity against these thermally dimorphic fungi. This suggests the potential clinical efficacy of manogepix for the treatment of emergomycosis and blastomycosis, which should be investigated in animal models of endemic mycoses and human clinical trials, as other indications are being investigated (10–15). *E. africanus* and *B. emzantsi* are currently known to be endemic only to Southern Africa, while *E. pasteurianus* is cosmopolitan.

**TABLE 1** Yeast-phase manogepix minimum inhibitory concentration distribution of 78 *Emergomyces africanus*, 2 *Emergomyces pasteurianus*, and 5 *Blastomyces emzantsi* clinical isolates

| No. of clinical isolates                | Minimum inhibitory concentration (mg/L) |        |       |       |       |       |              |
|-----------------------------------------|-----------------------------------------|--------|-------|-------|-------|-------|--------------|
|                                         | $<0.0005$                               | 0.0005 | 0.001 | 0.002 | 0.004 | 0.008 | $\geq 0.016$ |
| <i>Emergomyces africanus</i> (n = 78)   | 4                                       | 10     | 30    | 23    | 9     | 2     | 0            |
| <i>Emergomyces pasteurianus</i> (n = 2) | 1                                       | 0      | 0     | 0     | 1     | 0     | 0            |
| <i>Blastomyces emzantsi</i> (n = 5)     | 0                                       | 1      | 1     | 1     | 2     | 0     | 0            |

We have previously described the BMD MIC ranges of other antifungal classes against the yeast phases of *E. africanus* and *B. emzantsi*. For *E. africanus* ( $n = 50$ ), the MIC ranges were: fluconazole 0.12–1 mg/L, voriconazole 0.008–0.015 mg/L, posaconazole 0.008–0.25 mg/L, itraconazole 0.008–0.12 mg/L, 5FC 4–256 mg/L, caspofungin 0.06–8 mg/L, micafungin 0.12–8 mg/L, and anidulafungin 0.12–8 mg/L (9). In comparison with all other tested agents, manogepix had more potent activity against *E. africanus*. For *B. emzantsi* ( $n = 8$ ), the MIC ranges were: fluconazole 0.25–4 mg/L, voriconazole 0.008–0.03 mg/L, posaconazole 0.008–0.008 mg/L, itraconazole 0.008–0.12 mg/L, 5FC 16–128 mg/L, caspofungin 0.5–4 mg/L, micafungin 0.008–0.3 mg/L, and anidulafungin 0.5–2 mg/L (16). In comparison with all other tested agents, manogepix was also more potent against *B. emzantsi*.

Limitations of this study include (i) the lack of a standardized method for susceptibility testing, (ii) no breakpoints to interpret MICs, and (iii) a small number of tested *B. emzantsi* isolates. We did not test all fungal species that cause emergomycosis and blastomycosis, so these results cannot be generalized to other endemic areas of the world.

Fosmanogepix has been found to be safe in healthy volunteers (17) and is currently in Phase 2 clinical trials evaluating the efficacy and safety of both intravenous (IV) and oral formulations for the treatment of patients with invasive fungal infections (10). While there are no established clinical breakpoints for manogepix, the very low MICs provide evidence of potent *in vitro* activity against these thermally dimorphic fungi. This suggests the potential clinical efficacy of manogepix for the treatment of emergomycosis and blastomycosis, which could be further investigated in animal models and future clinical trials.

## AUTHOR AFFILIATIONS

<sup>1</sup>National Institute for Communicable Diseases (NICD), a Division of the National Health Laboratory Service, Johannesburg, South Africa

<sup>2</sup>School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Witwatersrand, South Africa

<sup>3</sup>Division of Medical Microbiology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

## AUTHOR ORCIDs

Silondwe P. Nzimande  <http://orcid.org/0000-0003-2618-8630>

Nelesh P. Govender  <http://orcid.org/0000-0001-7869-9462>

Tsidiso G. Maphanga  <http://orcid.org/0000-0002-6117-4309>

## FUNDING

| Funder                                                             | Grant(s) | Author(s)          |
|--------------------------------------------------------------------|----------|--------------------|
| Pfizer Inc.   Pfizer Pharmaceuticals (Pfizer Pharmaceuticals B.V.) |          | Nelesh P. Govender |

## REFERENCES

- Schwartz IS, Kenyon C, Thompson GR. 2016. Endemic mycoses: what's new about old diseases? *Curr Clin Microbiol Rep* 3:71–80. <https://doi.org/10.1007/s40588-016-0034-6>
- Kenyon C, Bonorchis K, Corcoran C, Meintjes G, Locketz M, Lehloeny R, Vismar HF, Naicker P, Prozesky H, van Wyk M, Bamford C, du Plooy M, Imrie G, Dlamini S, Borman AM, Colebunders R, Yansouni CP, Mendelson M, Govender NP. 2013. A dimorphic fungus causing disseminated infection in South Africa. *N Engl J Med* 369:1416–1424. <https://doi.org/10.1056/NEJMoa1215460>
- Thompson GR, Le T, Chindamporn A, Kauffman CA, Alastruey-Izquierdo A, Ampel NM, Andes DR, Armstrong-James D, Ayanlowo O, Baddley JW, et al. 2021. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of medical mycology in cooperation with the International society for human and animal mycology. *Lancet Infect Dis* 21:e364–e374. [https://doi.org/10.1016/S1473-3099\(21\)00191-2](https://doi.org/10.1016/S1473-3099(21)00191-2)
- Orlean P, Menon AK. 2007. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycosphospholipids. *J Lipid Res* 48:993–1011. <https://doi.org/10.1194/jlr.R700002-JLR200>
- Hager CL, Larkin EL, Long L, Zohra Abidi F, Shaw KJ, Ghannoum MA. 2018. *In vitro* and *in vivo* evaluation of the antifungal activity of

- APX001A/APX001 against *Candida auris*. Antimicrob Agents Chemother 62:e02319–17. <https://doi.org/10.1128/aac.02319-17>
6. Viriyakosol S, Kapoor M, Okamoto S, Covell J, Soltow QA, Trzoss M, Shaw KJ, Fierer J. 2019. APX001 and other Gwt1 inhibitor prodrugs are effective in experimental *Coccidioides immitis* pneumonia. Antimicrob Agents Chemother 63:01715–01718. <https://doi.org/10.1128/AAC.01715-18>
  7. Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR, Wiederhold N, Jenks JD. 2021. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 81:1703–1729. <https://doi.org/10.1007/s40265-021-01611-0>
  8. Wayne P, Clinical and laboratory standards Institute. 2008. CLSI document M27-A3 and supplement, p 6–12. In Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard
  9. Maphanga TG, Britz E, Zulu TG, Mpembe RS, Naicker SD, Schwartz IS, Govender NP. 2017. *In vitro* antifungal susceptibility of yeast and mold phases of isolates of dimorphic fungal pathogen *Emergomyces africanus* (formerly *Emmonsia* sp.) from HIV-infected South African patients. J Clin Microbiol 55:1812–1820. <https://doi.org/10.1128/JCM.02524-16>
  10. Vazquez JA, Pappas PG, Boffard K, Paruk F, Bien PA, Tawadrous M, Ople E, Wedel P, Oborska I, Hodges MR. 2023. Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by *Candida auris*: results from a phase 2 trial. Antimicrob Agents Chemother 67:e0141922. <https://doi.org/10.1128/aac.01419-22>
  11. Giamberardino CD, Schell WA, Tenor JL, Toffaletti DL, Palmucci JR, Marius C, Boua J-V, Soltow Q, Mansbach R, Moseley MA, Thompson JW, Dubois LG, Hope W, Perfect JR, Shaw KJ. 2022. Efficacy of APX2039 in a rabbit model of cryptococcal meningitis. mBio 13:e0234722. <https://doi.org/10.1128/mbio.02347-22>
  12. Lee A, Wang N, Carter CL, Zimmerman M, Dartois V, Shaw KJ, Perlin DS, Zhao Y. 2021. Therapeutic potential of fosmanogepix (APX001) for intra-abdominal candidiasis: from lesion penetration to efficacy in a mouse model. Antimicrob Agents Chemother 65:e02476–20. <https://doi.org/10.1128/AAC.02476-20>
  13. Petraitienė R, Petraitis V, Maung BBW, Mansbach RS, Hodges MR, Finkelman MA, Shaw KJ, Walsh TJ. 2021. Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of *Candida* endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits. Antimicrob Agents Chemother 65:e01795–20. <https://doi.org/10.1128/AAC.01795-20>
  14. Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, Filler SG, Ibrahim AS. 2020. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to *Rhizopus arrhizus*. Antimicrob Agents Chemother 64:e00178–20. <https://doi.org/10.1128/AAC.00178-20>
  15. Alkhazraji S, Gebremariam T, Alqarihi A, Gu Y, Mamouei Z, Singh S, Wiederhold NP, Shaw KJ, Ibrahim AS. 2020. Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis. Antimicrob Agents Chemother 64:e01735–19. <https://doi.org/10.1128/AAC.01735-19>
  16. Maphanga TG, Birkhead M, Muñoz JF, Allam M, Zulu TG, Cuomo CA, Schwartz IS, Ismail A, Naicker SD, Mpembe RS, Corcoran C, de Hoog S, Kenyon C, Borman AM, Frean JA, Govender NP. 2020. Human blastomycosis in South Africa caused by *Blastomyces persicus* and *Blastomyces emzantsi* sp. nov., 1967 to 2014. J Clin Microbiol 58:e01661–19. <https://doi.org/10.1128/JCM.01661-19>
  17. Hodges MR, Ople E, Wedel P, Shaw KJ, Jakate A, Kramer WG, Marle S van, van Hoogdalem E-J, Tawadrous M. 2023. Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers. Antimicrob Agents Chemother 67:e0162322. <https://doi.org/10.1128/aac.01623-22>